ONCY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Oncolytics Biotech Inc. (ONCY) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While the company has secured a significant patent for its key product, Pelareorep, and has a promising pipeline, the lack of strong trading signals, limited financial data, and neutral trading sentiment suggest that it is better to hold off on investing until more concrete growth or momentum is observed.
The MACD is positive and expanding, suggesting bullish momentum. RSI is neutral at 69.331, and moving averages are converging, indicating no clear trend. Key resistance is at 0.997, which is close to the current price of 0.9702, suggesting limited immediate upside.
The company secured a U.S. patent for Pelareorep, protecting it until 2044, which enhances its competitive edge and manufacturing scalability. Clinical trials for Pelareorep show promising results.
The stock has a historical probability of declining in the short term (-0.75% in the next day, -4.03% in the next week). Analyst Chad Messer recently lowered the price target from $7 to $5, reflecting tempered expectations.
No financial data available for analysis.
Lake Street analyst Chad Messer maintains a Buy rating but lowered the price target from $7 to $5, reflecting cautious optimism.
